Cart
sales@molnova.com
Butyzamide
CAS No. 1110767-45-7
Butyzamide( —— )
Catalog No. M36057 CAS No. 1110767-45-7
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 347 | In Stock |
|
| 5MG | 266 | In Stock |
|
| 10MG | 392 | In Stock |
|
| 25MG | 605 | In Stock |
|
| 50MG | 890 | In Stock |
|
| 100MG | 1349 | In Stock |
|
| 200MG | 1814 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameButyzamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionButyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which promotes proliferation of human Mpl (hMpl) expression and mouse pro B cell line Ba/F3.
-
DescriptionButyzamide is an orally active activator of Mpl, a thrombopoietin (TPO) receptor. Butyzamide increases the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. Butyzamide increases the level of human platelets in mouse xenotransplantation assay.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorThrombopoietin Receptor | JAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1110767-45-7
-
Formula Weight591.55
-
Molecular FormulaC29H32Cl2N2O5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (169.05 mM; Ultrasonic )
-
SMILESO(C)C1=C(C=CC=C1C(OCCC)C(C)(C)C)C=2N=C(NC(=O)C3=CC(Cl)=C(/C=C(/C(O)=O)\C)C(Cl)=C3)SC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
ZT55
ZT55 (JAK inhibitor ZT55) is a novel potent, highly-selective tyrosine kinase JAK2 inhibitor with IC50 of 31 nM.
-
JAK-IN-5
JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
